☒
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
DELAWARE
|
|
93-0987903
|
(STATE OR OTHER JURISDICTION OF
INCORPORATION OR ORGANIZATION)
|
|
(I.R.S. EMPLOYER
IDENTIFICATION NO.)
|
Large
accelerated filer
|
☐
|
Accelerated
filer
|
☐
|
Non-accelerated
filer
|
☐
|
Smaller
reporting company
|
☒
|
Emerging
growth company
|
☐
|
|
|
|
September
30,
2018
|
December
31,
2017
|
Assets
|
(Unaudited)
|
Note
1
|
Current
assets:
|
|
|
Cash and cash
equivalents
|
$
951,751
|
$
885,710
|
Prepaid
expenses
|
341,511
|
150,462
|
Other current
assets
|
141,872
|
171,346
|
Total current
assets
|
1,435,134
|
1,207,518
|
Property and
equipment, net
|
457,526
|
578,206
|
Goodwill
|
6,826,003
|
6,826,003
|
Other
assets
|
178,597
|
178,597
|
Total
assets
|
$
8,897,260
|
$
8,790,324
|
|
|
|
Liabilities
and Stockholders’ Equity
|
|
|
Current
liabilities:
|
|
|
Accounts
payable
|
$
2,447,175
|
$
1,090,904
|
Accrued
compensation
|
311,162
|
311,675
|
Accrued clinical
operations and site costs
|
2,106,295
|
1,669,201
|
Accrued lease
termination fee
|
590,504
|
590,504
|
Other accrued
expenses
|
442,210
|
404,923
|
Interest
payable
|
31,027
|
39,373
|
Current portion of
notes payable
|
1,822,062
|
1,681,876
|
Current portion of
capital lease payable
|
18,943
|
17,810
|
Total current
liabilities
|
7,769,378
|
5,806,266
|
Non-current
liabilities:
|
|
|
Non-current portion
of notes payable, net
|
813,039
|
1,621,483
|
Non-current portion
of capital lease payable
|
31,504
|
45,857
|
Other non-current
liabilities
|
240,781
|
186,278
|
Total non-current
liabilities
|
1,085,324
|
1,853,618
|
Total
liabilities
|
8,854,702
|
7,659,884
|
Commitments and
contingencies (Note 11)
|
|
|
Stockholders’
equity:
|
|
|
Series D
convertible preferred stock, $0.01 par value, 1,000,000 shares
authorized, 44,104 shares issued and outstanding as of September
30, 2018 and December 31, 2017, with a liquidation preference
of $441
|
441
|
441
|
Series E
convertible preferred stock, $0.01 par value, 100,000 shares
authorized, 33,333 shares issued and outstanding as of September
30, 2018 and December 31, 2017, with a liquidation preference
of $333
|
333
|
333
|
Series I
convertible preferred stock, $0.01 par value, 1,968,664 shares
authorized, 645,640 and 798,460 shares issued and outstanding as of
September 30, 2018 and December 31, 2017, respectively, with a
liquidation preference of $6,456 and $7,984 as of September 30,
2018 and December 31, 2017, respectively
|
6,456
|
7,984
|
Series J
convertible preferred stock, $0.01 par value, 3,400 shares
authorized, 772.73 shares issued and outstanding as of
September 30, 2018 and December 31, 2017, with a liquidation
preference of $531,252
|
8
|
8
|
Series K
convertible preferred stock, $0.01 par value, 65,000 shares
authorized, 63,150 shares issued and outstanding as of September
30, 2018 and December 31, 2017, with a liquidation preference of
$632
|
632
|
632
|
Series L
convertible preferred stock, $0.01 par value, 58,000 shares
authorized, 45,500 and 58,000 shares issued and outstanding as
of September 30, 2018, and December 31, 2017, respectively, with a
liquidation preference of $4,550,000 and $5,800,000 as of September
30, 2018 and December 31, 2017, respectively
|
455
|
580
|
Series M
convertible preferred stock, $0.01 par value, 10,000 shares
authorized, 5,000 and no shares issued and outstanding as of
September 30, 2018 and December 31, 2017, respectively, with a
liquidation preference of $1,500,000 and $0 as of September 30,
2018 and December 31, 2017, respectively
|
50
|
0
|
Series N
convertible preferred stock, $0.01 par value, 20,000 shares
authorized, 5,363.64 and no shares issued and outstanding as of
September 30, 2018 and December 31, 2017, respectively, with a
liquidation preference of $53.64 and $0 as of September 30, 2018
and December 31, 2017, respectively
|
54
|
0
|
Series O
convertible preferred stock, $0.01 par value, 20,000 shares
authorized, 10,605.56 and no shares issued and outstanding as of
September 30, 2018 and December 31, 2017, respectively, with a
liquidation preference of $106.06 and $0 as of September 30, 2018
and December 31, 2017, respectively
|
106
|
0
|
Common stock, $0.01
par value, 150,000,000 shares authorized, 9,254,582 and 6,862,928
shares issued and outstanding as of September 30, 2018 and
December 31, 2017, respectively
|
92,546
|
68,629
|
Additional paid-in
capital
|
118,291,361
|
112,105,470
|
Accumulated
deficit
|
(118,349,884
)
|
(111,053,637
)
|
Total
stockholders’ equity
|
42,558
|
1,130,440
|
Total liabilities
and stockholders’ equity
|
$
8,897,260
|
$
8,790,324
|
|
Three
Months Ended
|
Nine
Months Ended
|
||
|
September
30,
|
September
30,
|
||
|
2018
|
2017
|
2018
|
2017
|
Revenues:
|
|
|
|
|
License
agreements
|
$
4,000,000
|
$
—
|
$
4,700,000
|
$
—
|
Total
revenues
|
4,000,000
|
—
|
4,700,000
|
—
|
|
|
|
|
|
Cost of
revenues
|
785,000
|
—
|
785,000
|
—
|
Gross
Profit
|
3,215,000
|
—
|
3,915,000
|
—
|
|
|
|
|
|
Operating costs and
expenses:
|
|
|
|
|
Research
and development
|
199,367
|
1,017,061
|
2,915,709
|
6,168,125
|
General
and administrative
|
2,520,950
|
1,831,629
|
6,409,491
|
7,513,621
|
Total operating
costs and expenses
|
2,720,317
|
2,848,690
|
9,325,200
|
13,581,746
|
Income/(loss) from
operations
|
494,683
|
(2,848,690
)
|
(5,410,200
)
|
(13,681,746
)
|
Interest and other
expense
|
(154,002
)
|
(231,471
)
|
(497,868
)
|
(743,137
)
|
Net income
(loss)
|
340,681
|
(3,080,161
)
|
(5,908,068
)
|
(14,424,883
)
|
Deemed dividend on
inducement shares
|
—
|
—
|
(1,388,179
)
|
(5,220,000
)
|
Deemed dividend on
incentive shares
|
—
|
(3,120,000
)
|
—
|
(3,120,000
)
|
Deemed dividend on
warrant reprice
|
—
|
—
|
—
|
(19,413
)
|
Net income (loss)
allocable to common stockholders
|
$
340,681
|
$
(6,200,161
)
|
$
(7,296,247
)
|
$
(22,784,296
)
|
Basic net income
(loss) per share
|
$
0.04
|
$
(1.62
)
|
$
(0.81
)
|
$
(8.04
)
|
Diluted net income
(loss) per share
|
$
0.02
|
$
(1.62
)
|
$
(0.81
)
|
$
(8.04
)
|
|
|
|
|
|
S
hares used in
calculation of net income (loss) per share
|
|
|
|
|
Basic
|
9,253,880
|
3,830,280
|
8,983,980
|
2,834,692
|
Diluted
|
17,123,742
|
3,830,280
|
8,983,980
|
2,834,692
|
|
Series
D through O Convertible
Preferred
Stock
|
Common
Stock
|
Additional
Paid-in
|
Accumulated
|
Total
Stockholders'
|
||
|
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Deficit
|
Equity
|
Balance at
December 31, 2017
|
997,820
|
$
9,978
|
6,862,928
|
$
68,629
|
$
112,105,470
|
$
(111,053,637
)
|
$
1,130,440
|
Issuance of common
stock, Series M Convertible Preferred Stock and warrants in
connection with February 2018 financing
|
5,000
|
50
|
555,557
|
5,556
|
2,694,394
|
—
|
2,700,000
|
Issuance of common
stock, Series N Convertible Preferred Stock in connection with May
2018 financing
|
5,364
|
54
|
218,182
|
2,182
|
827,764
|
—
|
830,000
|
Issuance of
inducement shares of Series O Convertible Preferred Stock in
connection with May 2018 financing
|
10,606
|
106
|
—
|
—
|
(106
)
|
—
|
—
|
Deemed dividends on
inducement shares, May 2018
|
—
|
—
|
—
|
—
|
1,388,179
|
(1,388,179
)
|
—
|
|
|
|
|
|
|
|
|
Conversion of
Series I Preferred Stock to common stock
|
(152,820
)
|
(1,528
)
|
50,940
|
509
|
1,019
|
—
|
—
|
Conversion of
Series L Preferred Stock to common stock
|
(12,500
)
|
(125
)
|
694,445
|
6,944
|
(6,819
)
|
—
|
—
|
Issuance of whole
in lieu of fractional shares resulting from reverse split in
February 2018
|
—
|
—
|
50,991
|
510
|
(510
)
|
|
—
|
Common stock issued
upon vesting of restricted stock units in January 2018, net of
payroll taxes
|
—
|
—
|
797,977
|
7,980
|
(7,980
)
|
—
|
—
|
Common stock issued
upon vesting of restricted stock units in April 2018, net of shares
withheld for payroll taxes
|
—
|
—
|
22,061
|
221
|
(17,197
)
|
—
|
(16,976
)
|
Common stock issued
upon vesting of restricted stock units in August 2018
|
—
|
—
|
1,501
|
15
|
(15
)
|
—
|
—
|
Stock-based
compensation
|
—
|
—
|
—
|
—
|
1,307,162
|
—
|
1,307,162
|
Net
loss
|
—
|
—
|
|
—
|
—
|
(5,908,068
)
|
(5,908,068
)
|
Balance at
September 30, 2018
|
853,470
|
$
8,535
|
9,254,582
|
$
92,546
|
$
118,291,361
|
$
(118,349,884
)
|
$
42,558
|
|
Nine
Months
Ended
September 30,
|
|
|
2018
|
2017
|
Operating
activities
|
|
|
Net
loss
|
$
(5,908,068
)
|
$
(14,424,883
)
|
Adjustments to
reconcile net loss to net cash used in operating
activities:
|
|
|
Depreciation and
amortization
|
120,680
|
122,315
|
Stock-based
compensation
|
1,307,162
|
4,516,372
|
Issuance of
restricted stock for services
|
—
|
236,666
|
Amortization and
accretion related to notes payable
|
190,729
|
309,213
|
Increase (decrease)
in cash from changes in operating assets and
liabilities:
|
|
|
Other
receivables
|
29,474
|
(7,061
)
|
Prepaid expenses
and other
|
(189,916
)
|
(62,672
)
|
Accounts
payable
|
1,356,273
|
403,210
|
Accrued clinical
operations and site costs
|
437,094
|
283,864
|
Accrued
compensation
|
(513
)
|
(28,307
)
|
Other accrued
expenses
|
36,648
|
(51,649
)
|
Net cash used in
operating activities
|
(2,620,437
)
|
(8,702,932
)
|
|
|
|
Investing
activities
|
|
|
Purchases of
property and equipment
|
—
|
(21,072
)
|
Net cash used in
investing activities
|
—
|
(21,072
)
|
|
|
|
Financing
activities
|
|
|
February 2018
private placement, net of issuance costs
|
2,700,000
|
—
|
May 2018 and 2017
private placements, net of issuance costs
|
830,000
|
820,571
|
Proceeds from
issuance of common stock and Series G Preferred Stock, Net of
costs, May 2017
|
—
|
3,647,391
|
Proceeds from
issuance of common stock, net of costs, August 2017
|
—
|
125,000
|
Proceeds from
issuance of Series J Preferred Stock, net of costs, August
2017
|
—
|
1,189,417
|
Proceeds from
issuance of common stock, net of costs, September 2017
|
—
|
1,852,361
|
Proceeds from
issuance of common stock, net of costs, September 2017
|
—
|
1,215,000
|
Principal payments
on notes payable to Oxford Finance
|
(833,333
)
|
(972,223
)
|
Principal payments
on financed insurance policies
|
21,140
|
(69,240
)
|
Principal payments
on capital lease
|
(14,353
)
|
(10,785
)
|
Purchase of vested
employee stock in connection with tax withholding
obligation
|
(16,976
)
|
—
|
Net cash provided
by financing activities
|
2,686,478
|
7,797,492
|
Net change in cash
and cash equivalents
|
(66,041
)
|
(926,512
)
|
Cash and cash
equivalents at beginning of period
|
885,710
|
3,979,290
|
Cash and cash
equivalents at end of period
|
$
951,751
|
$
3,052,778
|
|
|
|
Supplemental
disclosures:
|
|
|
Cash
paid during the period for income taxes
|
$
1,900
|
$
1,600
|
Cash
paid during the period for interest on notes payable and the
capital lease
|
$
317,391
|
$
302,256
|
|
|
|
Supplemental
disclosures of non-cash investing and financing
information:
|
|
|
Deemed dividend on
issuance of inducement shares
|
$
1,388,179
|
$
5,220,000
|
Deemed dividend on
issuance of incentive shares
|
$
—
|
$
3,120,000
|
Conversion of
preferred stock to common stock – Series D
|
$
—
|
$
3,981
|
|
|
|
Conversion of
preferred stock to common stock – Series I
|
$
509
|
$
3,067
|
Conversion of
preferred stock to common stock – Series J
|
$
—
|
$
5,227
|
|
|
|
Conversion of
preferred stock to common stock – Series L
|
$
6,944
|
$
—
|
Fair value of
repricing warrants issued in previous financing
|
$
—
|
$
19,413
|
Common stock issued
upon vesting of RSUs
|
$
8,201
|
$
—
|
Years ending
December 31:
|
|
2018
(remaining)
|
$
36,348
|
2019
|
2,380,952
|
2020
|
396,826
|
Notes payable,
balance as of September 30, 2018
|
2,814,126
|
Unamortized
discount on notes payable
|
(179,025
)
|
Notes payable, net,
balance as of September 30, 2018
|
2,635,101
|
Current portion of
notes payable, net
|
(1,822,062
)
|
Non-current portion
of notes payable, net
|
$
813,039
|
|
Three
Months Ended
September
30,
|
Nine
Months Ended
September
30,
|
||
|
2018
|
2017
|
2018
|
2017
|
Risk-free interest
rate
|
-
|
-
|
2.4
%
|
1.5
to 2.0
%
|
Dividend
yield
|
-
|
-
|
0
%
|
0
%
|
Expected
volatility
|
-
|
-
|
87
%
|
73
to 85
%
|
Expected life of
options, in years
|
-
|
-
|
5.5 yrs.
|
1.4
to 6.0 yrs.
|
Weighted-average
grant date fair value
|
-
|
-
|
$
1.42
|
$
1.53
|
|
Three
Months Ended
|
Three
Months Ended
|
Nine
Months Ended
|
Nine
Months Ended
|
|
September
30,
|
September
30,
|
September
30,
|
September
30,
|
|
2018
|
2017
|
2018
|
2017
|
Research and
development
|
$
96,157
|
$
292,523
|
$
340,979
|
$
989,884
|
General and
administrative
|
172,458
|
721,213
|
966,183
|
3,526,488
|
Total stock-based
compensation expense
|
$
268,615
|
$
1,013,736
|
$
1,307,162
|
$
4,516,372
|
|
Options
Outstanding
|
Weighted-Average
Exercise
Price
|
Outstanding at
December 31, 2017
|
953,937
|
$
13.97
|
Granted
|
1,186,000
|
1.99
|
Exercised
|
—
|
—
|
Forfeited/cancelled/expired
|
(319,348
)
|
6.71
|
Outstanding and
expected to vest at September 30, 2018
|
1,820,589
|
$
7.44
|
Vested and
exercisable at September 30, 2018
|
1,060,093
|
$
10.24
|
|
Shares
|
Weighted
Average
Grant-Date
Fair
Value
|
Non-vested at
December 31, 2017
|
832,226
|
$
3.88
|
Granted
|
—
|
—
|
Vested
|
(832,226
)
|
50.26
|
Forfeited
|
—
|
—
|
Non-vested at
September 30, 2018
|
—
|
$
—
|
Common stock
reserved for conversion of preferred stock
|
7,869,862
|
Warrants to
purchase common stock
|
1,221,935
|
Common stock
options outstanding
|
1,820,589
|
Authorized for
future grant or issuance under the Stock Plan
|
646,059
|
Total
|
11,558,445
|
Board
Nomination:
|
|
To
nominate one (1) candidate to the Board of Directors acceptable to
the holder of a majority of the Series G Preferred Stock by
December 31, 2017, and that (2) two current Board members would
resign.
|
Executive
Hire:
|
|
To hire
a new C-level executive in a leadership role by July 15,
2017.
|
Board
Compensation:
|
|
To
issue an aggregate of 350,000 options to certain employees and
members of the Board of Directors, at a price not less than $6.00
per share, and 16,667 options to each other member of the Board of
Directors at the current market price in connection with this
offering. The options were issued pursuant to the Company’s
option plan, subject to the requisite approvals and availability
under the plan. The company was responsible for obtaining the
approval of the Board of Directors and stockholders of the Company
to the extent the company needed their approval to increase the
number of shares available under the plan. All Board of Director
fees were waived for 2017.
|
Funds
Held in Escrow:
|
|
$500,000
of the funds from the May 2017 Public Offering were to be held in
escrow and released to one or more investor relations services
acceptable to the Company following the closing of this
offering.
|
HS
Contrarian Investments, LLC
|
GRQ
Consultants, Inc. Roth 401K FBO Barry Honig Trustee
|
GRQ
Consultants, Inc. Roth 401K FBO Renee Honig Trustee
|
Grander
Holdings, Inc. 401K
|
Robert
B. Prag
|
David
Moss
|
Paradox
Capital Partners, LLC
|
Melechdavid,
Inc.
|
Melechdavid, Inc.
Retirement Plan
|
Robert
S. Colman Trust UDT 3/13/85
|
Sargeant Capital
Ventures, LLC
|
Edward
W. Easton TTEE The Easton Group ORP PSP U/A DTD
02/09/2000
|
Donald
E. Garlikov
|
Airy
Properties
|
Ryan
O'Rourke
|
Corey
Patrick O'Rourke
|
2018
(remaining)
|
$
5,601
|
2019
|
22,402
|
2020
|
22,402
|
2021
|
7,468
|
Less
interest
|
(7,426
)
|
Principal
|
50,447
|
Less current
portion
|
(18,943
)
|
Noncurrent
portion
|
$
31,504
|
2018
(remaining)
|
$
151,204
|
2019
|
466,085
|
2020
|
480,068
|
2021
|
494,470
|
2022
|
41,306
|
Total
|
$
1,633,133
|
|
Three
Months Ended
September
30,
|
%
Increase/
|
Nine
Months Ended
September
30,
|
%
Increase/
|
||
|
2018
|
2017
|
(Decrease)
|
2018
|
2017
|
(Decrease)
|
Revenues
|
$
4,000,000
|
$
-
|
100
%
|
$
4,700,000
|
$
-
|
100
%
|
Cost of
revenues
|
785,000
|
-
|
100
%
|
785,000
|
-
|
100
%
|
Gross
profit
|
$
3,215,000
|
-
|
100
%
|
$
3,915,000
|
-
|
100
%
|
|
|
|
|
|
|
|
|
Three
Months Ended
September
30,
|
%
Increase/
|
Nine
Months Ended
September
30,
|
%
Increase/
|
||
|
2018
|
2017
|
(Decrease)
|
2018
|
2017
|
(Decrease)
|
Research and
development
|
$
199,367
|
$
1,017,061
|
(80.4
)%
|
$
2,915,709
|
$
6,168,125
|
(52.7
)%
|
|
Three
Months Ended
September
30,
|
%
Increase/
|
Nine
Months Ended
September
30,
|
%
Increase/
|
||
|
2018
|
2017
|
(Decrease)
|
2018
|
2017
|
(Decrease)
|
General and
administrative
|
$
2, 520,950
|
$
1,831,629
|
37.6
%
|
$
6,409,491
|
$
7,513,621
|
(14.7
)%
|
|
Three
Months Ended
September
30,
|
%
Increase/
|
Nine
Months Ended
September
30,
|
%
Increase/
|
||
|
2018
|
2017
|
(Decrease)
|
2018
|
2017
|
(Decrease)
|
Interest and other
expense
|
$
(154,002
)
|
$
(231,471
)
|
(32.3
)%
|
$
(497,689
)
|
$
(743,137
)
|
(33.0
)%
|
|
Nine
Months Ended
September
30,
|
|
|
2018
|
2017
|
Cash provided by
(used in):
|
|
|
Operating
activities
|
$
(2,620,437
)
|
$
(8,702,932
)
|
Investing
activities
|
$
—
|
$
(21,072
)
|
Financing
activities
|
$
2,686,478
|
$
3,897,063
|
|
|
|
Exhibit
No.
|
Exhibit
Name
|
Filed
with
this Form 10-Q
|
Asset
Purchase and License Agreement with Boehringer Ingelheim
International GmbH
|
X
|
|
Certification of
Chief Executive Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
|
X
|
|
Certification of
Chief Financial Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
|
X
|
|
Certification
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
|
X
|
|
101*
|
Interactive data
file
|
|
|
|
|
Date:
November 13, 2018
|
MABVAX
THERAPEUTICS HOLDINGS, INC.
|
|
|
|
|
|
By:
|
/s/ J.
David Hansen
|
|
|
J.
David Hansen
|
|
|
President
and Chief Executive Officer
(Principal
Executive Officer authorized
to sign
on behalf of the registrant)
|
|
|
|
|
|
|
|
By:
|
/s/
Gregory P. Hanson
|
|
|
Gregory
P. Hanson
|
|
|
Chief
Financial Officer
(Principal
Financial and Accounting Officer
authorized
to sign on behalf of the registrant)
|
Clause
|
|
Page
|
1.
|
DEFINITIONS
|
3
|
2.
|
SALE AND PURCHASE OF THE ACQUIRED ASSETS
|
10
|
3.
|
LICENSE GRANT
|
10
|
4.
|
[***] RIGHTS
|
10
|
5.
|
PAYMENT
|
11
|
6.
|
CLOSING
|
13
|
7.
|
REPRESENTATIONS AND WARRANTIES
|
13
|
8.
|
COVENANTS
|
17
|
9.
|
TREATMENT OF CONFIDENTIAL INFORMATION
|
21
|
10.
|
CONDITIONS TO MABVAX’S OBLIGATION TO CLOSE
|
22
|
11.
|
CONDITIONS TO BII’S OBLIGATION TO CLOSE
|
22
|
12.
|
INDEMNITY AND LIMITATIONS OF LIABILITY
|
23
|
13.
|
DISPUTE RESOLUTION
|
25
|
14.
|
TERM, EXPIRATION, AND TERMINATION
|
26
|
15.
|
MISCELLANEOUS
|
28
|
Milestone Event
|
Milestone
Payment
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
MabVax Therapeutics Holdings,
Inc
.
:
|
|
|
|
|
|
|
July 4, 2018
|
By:
|
/s/
J. David
Hansen
|
|
|
|
J. David
Hansen
|
|
|
|
President and
CEO
|
|
|
MabVax Therapeutics, Inc
.
|
|
|
|
|
|
|
July 4, 2018
|
By:
|
/s/ J. David
Hansen
|
|
|
|
J. David
Hansen
|
|
|
|
President and
CEO
|
|
|
Boehringer
Ingelheim International GmbH:
|
|
|
|
ppa
|
|
|
|
|
|
|
July 4,
2018
|
By:
|
/s/
Marc
Wittstock
|
|
|
|
Marc
Wittstock
|
|
|
|
(Authorized
Signatory)
|
|
|
Boehringer Ingelheim International GmbH
|
|
|
|
ppa
|
|
|
|
|
|
|
July 4,
2018
|
By:
|
/s/
Martin
Mauer
|
|
|
|
Martin
Mauer
|
|
|
|
(Authorized
Signatory)
|
|
|
Seller:
|
|
|
|
MabVax Therapeutics Holdings, Inc.
|
|
|
|
By:
|
/s/ J.
David Hansen
|
|
Name:
|
J.
David Hansen
|
|
|
Title:
|
President
and CEO
|
|
|
Date:
|
July 4,
2018
|
|
|
|
MabVax
Therapeutics, Inc.
|
|
|
|
By:
|
/s/ J.
David Hansen
|
|
|
Name:
|
J.
David Hansen
|
|
|
Title:
|
President and
CEO
|
|
|
Date:
|
July 4,
2018
|
|
|
Buyer:
|
|
|
|
Boehringer Ingelheim International GmbH
ppa.
|
|
|
|
By:
|
/s/
Marc Wittstock
|
|
Name:
|
Marc
Wittstock
|
|
|
Title:
|
(Authorized
Signatory)
|
|
|
Date:
|
July 4,
2018
|
|
|
|
|
|
|
Boehringer Ingelheim International GmbH
ppa.
|
|
|
|
By:
|
/s/
Martin Mauer
|
|
Name:
|
Martin
Mauer
|
|
|
Title:
|
(Authorized
Signatory)
|
|
|
Date:
|
July 4,
2018
|
|
|
|
|
|
|
|
|
|
|
Seller:
|
|
|
|
MabVax Therapeutics Holdings, Inc.
|
|
|
|
By:
|
/s/ J.
David Hansen
|
|
Name:
|
J.
David Hansen
|
|
|
Title:
|
President
and CEO
|
|
|
Date:
|
July 4,
2018
|
|
|
|
MabVax
Therapeutics, Inc.
|
|
|
|
By:
|
/s/ J.
David Hansen
|
|
|
Name:
|
J.
David Hansen
|
|
|
Title:
|
President and
CEO
|
|
|
Date:
|
July 4,
2018
|
|
|
Buyer:
|
|
|
|
Boehringer Ingelheim International GmbH
ppa.
|
|
|
|
By:
|
/s/
Marc Wittstock
|
|
Name:
|
Marc
Wittstock
|
|
|
Title:
|
(Authorized
Signatory)
|
|
|
Date:
|
July 4,
2018
|
|
|
|
|
|
|
Boehringer Ingelheim International GmbH
ppa.
|
|
|
|
By:
|
/s/
Martin Mauer
|
|
Name:
|
Martin
Mauer
|
|
|
Title:
|
(Authorized
Signatory)
|
|
|
Date:
|
July 4,
2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
COUNTRY
|
SERIAL NO.
|
Attorney Docket NO.
|
ASSIGNEE
|
INVENTORS
|
PRIORITY FILING DATE
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***][***]
|
[***][***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***][***]
|
[***][***]
|
[***]
|
[***]
|
MabVax Therapeutics Holdings Inc.
/s/ J.
David Hansen
_______________________
Name:
J. David Hansen
Authorized
Signatory
[Place],___July
4, 2018__________
(date)
MabVax Therapeutics Inc.
/s/ J.
David Hansen
_______________________
Name:
J. David Hansen
Authorized
Signatory
|
[***]
[***]
_______________________
Name:
[***]
Authorized
Signatory
|
|
|
|
|
Date:
November 13, 2018
|
|
By:
|
/s/ J.
David Hansen
|
|
|
|
J.
David Hansen
|
|
|
|
Chief
Executive Officer (Principal
Executive
Officer)
|
|
|
|
|
Date:
November 13, 2018
|
|
By:
|
/s/
Gregory P. Hanson
|
|
|
|
Gregory
P. Hanson
|
|
|
|
Chief
Financial Officer (Principal
Financial
and Accounting Officer)
|
|
|
|
|
Date:
November 13, 2018
|
|
By:
|
/s/ J.
David Hansen
|
|
|
|
J.
David Hansen
|
|
|
|
Chief
Executive Officer (Principal
Executive
Officer)
|
|
|
|
|
Date:
November 13, 2018
|
|
By:
|
/s/
Gregory P. Hanson
|
|
|
|
Gregory
P. Hanson
|
|
|
|
Chief
Financial Officer (Principal
Financial
and Accounting Officer)
|